Literature DB >> 23909381

Prognostic factors associated with healing of venous leg ulcers: a multicentre, prospective, cohort study.

G Chaby1, P Senet, O Ganry, A Caudron, D Thuillier, C Debure, S Meaume, F Truchetet, P Combemale, F Skowron, P Joly, C Lok.   

Abstract

BACKGROUND: Some prognostic markers of venous leg ulcer (VLU) healing have been evaluated, mostly in retrospective studies.
OBJECTIVES: To identify which clinical characteristics, among those known as possible prognostic factors of VLU healing, and which VLU-associated sociodemographic and psychological factors, are associated with complete healing at week 24 (W24).
METHODS: A prospective, multicentre, cohort study was conducted in 22 French dermatology departments between September 2003 and December 2007. The end point was comparison between healed and nonhealed VLUs at W24, for patient clinical and biological characteristics; psychological, cognitive and social assessments; affected leg inclusion characteristics; venous insufficiency treatment and percentage of initial wound area reduction during follow-up.
RESULTS: In total, 104 VLUs in 104 patients were included; 94 were analysed. The mean VLU area and duration were 36.8 ± 55.5 cm2 and 24.8 ± 45.7 months, respectively. At W24, 41/94 VLUs were healed. Univariate analysis significantly associated complete healing with superficial venous surgery (P = 0.001), adherence to compression therapy at W4 (P = 0.03) and W24 (P = 0.01), ankle-joint ankylosis (P = 0.01) and mean percentage of VLU area reduction at W4 (P = 0.04). Multivariate analysis retained superficial venous surgery during follow-up [odds ratio (OR) 8.4, 95% confidence interval (CI) 1.9-48.2] and percentage reduction of the VLU area at W4 (OR 1.6, 95% CI 1.0-2.14) as being independently associated with healing.
CONCLUSIONS: These results indicate that complete healing of long-standing, large VLUs is independently associated with ablation of the incompetent superficial vein and percentage of wound area reduction after the first 4 weeks of treatment.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2013        PMID: 23909381     DOI: 10.1111/bjd.12570

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

Review 1.  Leg Ulcers in Sickle-Cell Disease: Treatment Update.

Authors:  Jean-Benoît Monfort; Patricia Senet
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-04-24       Impact factor: 4.730

2.  Methacrylate dressing on refractory venous leg ulcers.

Authors:  Rafael García Carretero; Maria Garrido-Ollero; Ana Martinez-Alvarez; Ana Cadenas-Vara
Journal:  BMJ Case Rep       Date:  2018-03-15

3.  Epidemiology and use of compression treatment in venous leg ulcers: nationwide claims data analysis in Germany.

Authors:  Kristina Heyer; Kerstin Protz; Gerd Glaeske; Matthias Augustin
Journal:  Int Wound J       Date:  2016-05-19       Impact factor: 3.315

Review 4.  Challenging passivity in venous leg ulcer care - the ABC model of management.

Authors:  Keith Harding
Journal:  Int Wound J       Date:  2016-05-05       Impact factor: 3.315

Review 5.  Protease activity as a prognostic factor for wound healing in venous leg ulcers.

Authors:  Maggie J Westby; Jo C Dumville; Nikki Stubbs; Gill Norman; Jason Kf Wong; Nicky Cullum; Richard D Riley
Journal:  Cochrane Database Syst Rev       Date:  2018-09-01

6.  Potential prognostic factors for delayed healing of common, non-traumatic skin ulcers: A scoping review.

Authors:  David A Jenkins; Sundus Mohamed; Joanne K Taylor; Niels Peek; Sabine N van der Veer
Journal:  Int Wound J       Date:  2019-02-28       Impact factor: 3.315

7.  Inflammatory signals and network connections implicate cell-mediated immunity in chronic venous insufficiency.

Authors:  Lena Vodovotz; Ruben Zamora; Derek A Barclay; Yoram Vodovotz; Jinling Yin; Julie Bitner; John Florida; Efthymios D Avgerinos; Ulka Sachdev
Journal:  Ann Transl Med       Date:  2021-11

8.  Primary care disease management for venous leg ulceration-study protocol for the Ulcus Cruris Care [UCC] randomized controlled trial (DRKS00026126).

Authors:  Jonas D Senft; Thomas Fleischhauer; Jona Frasch; Wiebke van Rees; Manuel Feißt; Simon Schwill; Christine Fink; Regina Poß-Doering; Michel Wensing; Uwe Müller-Bühl; Joachim Szecsenyi
Journal:  Trials       Date:  2022-01-20       Impact factor: 2.279

9.  Development of a model to predict closure of chronic wounds in Germany: Claims data analysis.

Authors:  Kristina Hagenström; Kerstin Protz; Jana Petersen; Matthias Augustin
Journal:  Int Wound J       Date:  2021-05-05       Impact factor: 3.315

10.  Allogeneic ABCB5+ mesenchymal stem cells for treatment-refractory chronic venous ulcers: a phase I/IIa clinical trial.

Authors:  Andreas Kerstan; Kathrin Dieter; Elke Niebergall-Roth; Ann-Kathrin Dachtler; Korinna Kraft; Markus Stücker; Georg Daeschlein; Michael Jünger; Tobias Görge; Ulrich Meyer-Pannwitt; Cornelia Erfurt-Berge; Charlotte von Engelhardt; Andreas Klare; Christiane Pfeiffer; Jasmina Esterlechner; Hannes M Schröder; Martin Gasser; Ana M Waaga-Gasser; Matthias Goebeler; Seda Ballikaya; Samar Sadeghi; George F Murphy; Dennis P Orgill; Natasha Y Frank; Christoph Ganss; Karin Scharffetter-Kochanek; Markus H Frank; Mark A Kluth
Journal:  JID Innov       Date:  2021-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.